N/A N=55 Progression of Airway Obstruction in Childhood Asthma
Asthma
Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=233 Asthma Symptom Management Through Mindfulness Training
Asthma
Primary: Change From Baseline in Asthma Control at 18 Months — 1.27; 1.17 score on a scale
N/A N=43 Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease
Asthma · Pulmonary Disease, Chronic Obstructive
Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml
Phase 3 N=1,771 Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)
Asthma
Primary: Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment Period — 0.99; 1.06; 1.05 Asthma attacks within episodes per year — p=0.510
Phase 2 N=49 Oxidative Stress in Asthma
Asthma · Obesity
Primary: Percentage of Neutrophils in Peripheral Blood — 57.3; 55.4 percentage of neutrophils — p=0.53
Phase 2 N=248 Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma
Asthma
Primary: Peak Change From Baseline in FEV1 Within 3 Hours Post-dosing on Day 15 — 0.284; 0.261; 0.252; 0.237 Liter
N/A N=21 Positive Airway Pressure for the Treatment of Asthma
Asthma · Sleep Apnea
Primary: Asthma Control Test — 19.3; 19.8; 19.1; 19.6 units on a scale — p=0.8
Phase 3 N=210 Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)
Asthma
Primary: Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF) — 24.4; 18.0; -1.4 Liters per minute
Phase 2 N=134 Study of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma (0476-386)
Asthma
Primary: Change From Baseline in FEV1 (Forced Expiratory Volume; Volume of Air That is Exhaled During the First Second of a Forced Exhalation) — 0.22; 0.17 L (Liter) — p=0.033
N/A N=7 Imaging Study of the Lungs During an Allergic Asthma Attack
Asthma · Atopy
Primary: Percentage Change in the Ratio of Mean-normalized Perfusion Within Ventilation Defective Regions Relative to Outside — -17.8 percentage
Phase 3 N=689 Chronic Asthma Study in 2- to 5-Year-Old Patients (MK0476-072 )
Asthma
Primary: Number of Patients With Clinical Adverse Experiences (CAE) Reported by Patients - Base Study — 202; 406; 26; 55 Participants
Early Phase 1 N=39 Defining and Treating Depression-related Asthma
Asthma · Depression · Childhood Asthma
Primary: FEV1 Percent Change Post-ipratropium — 10.8 percent change — p=0.032
Phase 3 N=1,162 Montelukast Back to School Asthma Study (0476-340)
Asthma
Primary: Mean Percentage of Days With Worsening Asthma (as Measured on Daily Diaries) in Pediatric Asthmatic Participants — 27.23; 24.26 Percentage of Days
Phase 4 N=25 Single Dose Bronchodilatory Study in Asthma
Asthma
Primary: Change From Baseline in FEV1 — 2.84 Liter
N/A N=18 Airway Smooth Muscle and Asthma Severity
Asthma
Primary: Difference in ASM Mass Between Groups
N/A N=59 Modulation Of Airway Reactivity With Chronic Mechanical Strain
Asthma
Primary: Change in Airway Reactivity From Baseline (Visit 1) and 4 Weeks (Visit 2) — 3.0; 3.2; 5.3; 4.3 mg/mL
Phase 2 N=68 Symptom Clusters in Children With Exacerbation-prone Asthma
Asthma in Children
Primary: Change in Asthma Control Questionnaire (ACQ) Score — 0.52 score on a scale
Phase 3 N=122 GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants
Phase 2 N=15 A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma
Severe, Refractory Asthma · Airway Inflammation · Airflow Obstruction
Primary: 16 Weeks - Juniper Asthma Quality of Life Questionnaire (AQLQ) Score — 4.7; 4.6 units on a scale
Phase 2 N=21 Personalized Treatment Algorithms for Difficult-to-treat Asthma
Asthma in Children
Primary: Change in Composite Asthma Severity Index (CASI) — 5; 5; 5 score on a scale — p=0.52
Phase 3 N=421 Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)
Asthma
Primary: Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3 — 9.53; 9.15 Percent Change
N/A N=1,899 Exacerbation Risk in Asthma
Asthma
Primary: Time to First Severe Exacerbation — 43.75; 49.43 Days — p=0.758
N/A N=288 Non-Interventional Study to Describe the Clinical Management in Asthmatic Patients (NICMA)
Asthma
Primary: Clinical Management in Asthmatic Patients — 60; 64; 29; 41 Participants
Phase 3 N=186 A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics
Asthma
Primary: Baseline Adjusted Percent Predicted Forced Expiratory Volume In 1 Second (FEV1) Area Under The Concentration Time Curve Up From Time Zero up to 6 Hours (AUC0-6) Over 3…
Early Phase 1 N=9 In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma
Asthma
Primary: Concentration (pg/ml) of CXCL8 Cytokine in Cell Supernatant After Stimulation (IFN/TNF or IL13) and Treatment (VR588, FP or CP) Conditions in ALI Cultured Epithelial…
N/A N=292 Asthma in Central Texas Project
Asthma
Primary: Absenteeism, End of Study — 3.83; 4.41; 3.68 percentage of days enrolled
Phase 3 N=92 Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA)
Asthma
Primary: Juniper Asthma Control Questionnaire (ACQ) Results — -0.15; -0.38 units on a scale
Phase 3 N=1,437 TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)
Asthma
Primary: 1_Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Week 26 — 0.229; 0.157; 0.274 Liter — p=0.003
Phase 2 N=64 Roflumilast Plus Montelukast in Adults With Severe Asthma
Asthma
Primary: Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) — 0.18; 0.08 liters — p=0.013
Phase 3 N=342 Asthma Clinical Research Network (ACRN) Trial - Best Adjustment Strategy for Asthma in Long Term (BASALT)
Asthma
Primary: Time to Treatment Failure (Measured in Days) — 196.9; 225.2; 182.3 days